Evaluating the performance of Retail Pharmacy USA division

Walgreens Boots Alliance’s (WBA) 1Q18 top-line growth was driven by strong performances from all three of its divisions. We’ll discuss the Retail Pharmacy USA division in this part of our series, and in the next part we’ll focus on the company’s international businesses.

The Retail Pharmacy USA division, which accounted for 73.2% of its 1Q18 sales, recorded 8.9% YoY growth in total sales. Pharmacy sales increased by an impressive 14% during the quarter, driven by higher prescription volume.

While the company was hit by a reduction in reimbursement rates and a fall in generics, its pharmacy sales got a boost from solid momentum in its mail services and central specialty pharmacy, operated under AllianceRx Walgreens Prime.

Walgreens’s US Pharmacy Sales Strong, Retail Sales Still Soft

Comparable pharmacy sales rose 7.4% during the quarter. Prescriptions filled in comparable stores were up 8.9% YoY, driven primarily by volume growth from its previously announced strategic partnerships and Medicare Part D growth. In comparison, Rite Aid (RAD) recorded a 2.4% decline in the number of prescriptions filled in the same stores (adjusted to 30-day equivalents).

US Retail remains soft

Walgreens’ retail division, however, remained a laggard. Its same-store sales fell for the sixth straight quarter. Sales comps were down 0.9%, hurt by weak demand for personal care products and general merchandise category. Total retail sales decreased 2.8% during the quarter.

The recent softness in retail sales has raised doubts about Walgreens’s acquisition of 1,932 Rite Aid stores.

“From our perspective, it may take at least a handful of years before Walgreens is able to fully benefit from the acquisition,” said Morningstar analyst Vishnu Lekraj.

Margins come under pressure

Gross margins at the Retail Pharmacy USA business plunged 140 basis points to 24.9%. Margins were hit by lower reimbursement rates and higher sales of low-cost generic drugs.

Read about the company’s remaining segments in the next part of this series.

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.